English

Gradientech: Interim report 1 January – 31 March 2023

Report this content

Gradientech AB (publ) interim report for Q1 2023 is now available on the company's website www.gradientech.se.

First quarter January-March 2023

  • Net sales amounted to KSEK 380 (0).
  • Profit after tax amounted to KSEK -18,063 (-15,171).
  • Earnings per share before and after dilution were SEK -1.08 (-1.04).
  • Cash flow from operating activities amounted to KSEK -18,068 (-14,982).
  • Cash and cash equivalents on the balance sheet date amounted to KSEK 25,993 (74,020).
  • Equity as of March 31, 2023 amounted to KSEK 40,731 (78,598).
  • On January 18, 2023, the subscription period for the rights issue ended, which started on December 27, 2022. The final outcome comprised a total of 1,271,057 subscribed shares, which provided Gradientech with approximately SEK 26.1 million before deduction of issue costs. As a result of the Rights Issue, the share capital increased by SEK 127,105.70 to a total of SEK 1,724,525.00 and the number of shares increased by 1,271,057 to a total of 17,245,250 shares.

Significant events after the end of the period

  • Within the framework of the authorization granted by the Annual General Meeting, the Board of Directors resolved on 4 April 2023 to carry out a directed issue to the commercial partner a.d.a SRL of 550,000 shares at a price of SEK 20.50 per share. As a result of the directed issue, the share capital increased by SEK 55,000 to a total of SEK 1,779,525.00 and the number of shares increased to a total of 17,795,250 shares. The issue was registered with the Swedish Companies Registration Office on April 25, 2023.
  • In April, Gradientech exhibited at ECCMID in Copenhagen, the world's leading congress for both industry and clinic in clinical microbiology and infectious diseases. At the congress, Gradientech presented data confirming that QuickMIC® provides accurate results in 2-4 hours.

For more information please contact:
Sara Thorslund, PhD, CEO Gradientech
Tel: +46 736 29 35 80
sara.thorslund@gradientech.se

Urban Adolfsson, CFO
urban.adolfsson@gradientech.se   

Ann Charlotte Svensson, Investor Relations
ir@gradientech.se
 

About Gradientech
Gradientech is leading the field of ultra-rapid antibiotic susceptibility testing. We develop next-generation diagnostics in infectious disease medicine. Our product QuickMIC allows patients with sepsis to quickly receive specific guidance on the right antibiotic in the right dose. It saves lives, reduces healthcare costs and limits the spread of antibiotic resistance – one of the greatest global health threats of our time. Gradientech is headquartered in Uppsala, Sweden. Visit gradientech.se for more information.

Subscribe

Documents & Links